SEC Filing Summary: Amprius Technologies, Inc. (AMPX)
Business Context and Reporting Period
This Form 8-K was filed by Amprius Technologies, Inc. on September 19, 2024. The report addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial metric disclosed is the market price of the Company's common stock, which averaged less than $1.00 over a consecutive 30 trading-day period, triggering the non-compliance notice.
Material Changes
The primary material event is the receipt of a notice from the NYSE on September 19, 2024, stating that the Company failed to meet Section 802.01C of the NYSE Listed Company Manual due to the low average closing share price. No other material changes to operations or financial condition are detailed in this specific report.
Outlook, Risks, and Contingencies
- Compliance Timeline: The Company has a six-month cure period from the date of the notice to regain compliance.
- Remediation Requirements: To cure the deficiency, the Company must achieve a closing price of at least $1.00 per share on the last trading day of any calendar month during the cure period and maintain an average closing share price of at least $1.00 over the 30 trading-day period ending on that date.
- Trading Status: The Company's common stock will continue to be listed and traded on the NYSE during the cure period, provided it complies with other applicable listing rules.
- Management Action: On September 20, 2024, the Company issued a press release acknowledging the notice and stating its intention to regain compliance.
Investor Verification Checklist
- Verify the current trading price of AMPX to assess progress toward the $1.00 threshold.
- Monitor the Company's press releases for updates on the cure plan and any potential reverse stock splits.
- Review the attached Exhibit 99.1 (Press Release) for additional management commentary on the situation.
- Check subsequent filings for any updates on the six-month cure period status.